William G. Cohen

William G. Cohen

Auto-generated profile, based on publicly available information

William G. Cohen

Department of Otolaryngology – Head and Neck Surgery, Vanderbilt University Medical Center, Nashville, TN

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 April 2023 in ASAIO Journal
Verified
Journal Article
Closed access
WCWilliam G. Cohen
William G. Cohen
DRDavid Rekhtman
David Rekhtman
AIAmit Iyengar
Amit Iyengar
MSMax Shin
Max Shin
MIMichael Ibrahim
Michael Ibrahim
JWJoyce Wald
Joyce Wald
We report midterm results of Impella 5.5 use with focus placed on bridge-outcomes, venoarterial extracorporeal membrane oxygenation (VA-ECMO) transition, complications, and risk factors for mortality. A retrospective review of patients implanted with the Impella 5.5 at our medical center was conducted. Forty patients were included with varying bridge strategies. Sixteen (40%) patients were supported for 30 days. Thirty day mortality was 22.5% (9/40). Twenty-five (62.5%) were successfully bridged to transplant or durable left ventricular assist device (LVAD), while four (10.0%) recovered without the need for any further cardiac support. Five of 11 (60%) patients initially supported with VA-ECMO were either transitioned to durable left ventricular assist device (dLVAD; n = 3, 27.3%), transplanted (n = 1, 9.1%), or recovered (n = 1, 9.1%). Of nine patients with >moderate right ventricle (RV) dysfunction, five (55.6%) were successfully bridged to transplant or LVAD. Five (12.5%) patients required interval cannulation to VA-ECMO, often in the setting of RV dysfunction, and all (100%) were successfully transplanted. Lower pulmonary artery (PA) systolic pressure (P = 0.029), among other factors, was associated with mortality. In summary, the Impella 5.5 may be able to effectively stabilize patients in refractory left ventricular predominant cardiogenic shock for extended durations, allowing time for mechanical circulatory support (MCS) and transplant evaluations.

9 November 2020 in ASAIO Journal
Verified
Journal Article
Closed access
WCWilliam Cohen
William Cohen
PCPamela Combs
Pamela Combs
CEChawki El-Zein
Chawki El-Zein
MIMichel Ilbawi
Michel Ilbawi
GKGene Kim
Gene Kim
NHNarutoshi Hibino
Narutoshi Hibino
Infants are a unique transplant population due to a suspected immunologic advantage, in addition to differences in size and physiology. Consequently, we expect infants to have significantly different diagnoses, comorbidities, and outcomes than pediatric transplant recipients. In this study, we compare patterns and trends in pediatric and infant heart transplantation during three decades. The United Network for Organ Sharing (UNOS) database was queried for transplants occurring between January 1990 and December 2018. Patients were categorized as pediatric (1–17) or infant (0–1). Congenital heart disease (CHD) primary diagnoses have increased from 37% to 42% in pediatric patients (p = 0.001) and decreased from 80% to 61% in infants during the 1990s and 2010s (p < 0.001). Those with CHD had worse outcomes in both age groups (p < 0.001). Infants who underwent ABO-incompatible transplants had similar survival as compared to those with compatible transplants (p = 0.18). Overall, infants had better long-term survival and long-term graft survival than pediatric patients; however, they had worse short-term survival (p < 0.001). Death due to rejection or graft failure was less likely in infants (p = 0.034). However, death from infection was over twice as common (p < 0.001). In summary, pediatric and infant heart transplant recipients differ in diagnoses, comorbidities, and outcomes, necessitating different care for these populations.

6 August 2020 in Head & Neck
Verified
Journal Article
Closed access
PDF file
WCWilliam Cohen
William Cohen
SMSaeid Mirzai
Saeid Mirzai
PCPamela Combs
Pamela Combs
RRRebecca Rose
Rebecca Rose
VKViktoriya Kagan
Viktoriya Kagan
TSTae Song
Tae Song

19 February 2023 in The Journal of Heart and Lung Transplantation
Verified
Journal Article
Closed access
MSMax Shin
Max Shin
AIAmit Iyengar
Amit Iyengar
MHMark R. Helmers
Mark R. Helmers
WPWilliam L. Patrick
William L. Patrick
WCWilliam Cohen
William Cohen
MCMarisa Cevasco
Marisa Cevasco

21 March 2024 in World Journal of Otorhinolaryngology - Head and Neck Surgery
Verified
Journal Article
Open access
PDF file
LBLouis‐Xavier Barrette
Louis‐Xavier Barrette
WCWilliam G. Cohen
William G. Cohen
TCTiffany Chao
Tiffany Chao
JDJennifer E. Douglas
Jennifer E. Douglas
JKJames Kearney
James Kearney
KRKarthik Rajasekaran
Karthik Rajasekaran
Objectives: Enhanced recovery after surgery (ERAS) protocols for endoscopic sinus surgery (ESS) have not been widely implemented, and a critical review of ERAS recommendations and a comprehensive analysis of the supporting literature has not been undertaken. We describe an ESS ERAS protocol including key perioperative interventions for patients undergoing ESS and assess the available evidence.Data Sources: A search was conducted of all relevant ERAS literature in otorhinolaryngology, anesthesia, and surgery using Medline (via PubMed), and Scopus. Keywords included “endoscopic sinus surgery,” “sinus surgery,” “FESS,” and “ESS” for each area of intervention. Where applicable, the authors considered high‐level evidence for recommendations devised for patient cohorts in otorhinolaryngology not undergoing ESS, as well as cohorts undergoing surgical procedures for which ERAS protocols have been extensively evaluated.Methods: Studies received grades of “low,” “moderate,” or “high” quality evidence based on the Oxford Centre for Evidence‐Based Medicine criteria. Each intervention was subsequently assigned a grade of “strong,” “weak,” or “conditional” based on the available evidence.Results: Strong recommendations include comprehensive patient education and counseling, minimization of preoperative fasting, application of topical/local anesthetics and vasoconstrictors, use of total intravenous anesthesia, avoidance of pharyngeal packing, and use of postoperative nasal irrigation and multimodal analgesia. Conditional recommendations include antibiotic prophylaxis. Weak recommendations include perioperative venous thromboembolism prophylaxis, controlled hypotension, and use of postoperative nasal packing/dressing.Conclusion: A comprehensive ERAS protocol for ESS can include a variety of high yield, evidence‐based interventions that would likely improve surgical outcomes and patient satisfaction.

8 September 2022 in ASAIO Journal
Verified
Journal Article
Closed access
AIAmit Iyengar
Amit Iyengar
WCWilliam Cohen
William Cohen
JHJason Han
Jason Han
MHMark Helmers
Mark Helmers
JKJohn J. Kelly
John J. Kelly
PAPavan Atluri
Pavan Atluri
The coronavirus disease 2019 (COVID-19) pandemic continues to pose a significant threat to patients receiving advanced heart failure therapies. The current study was undertaken to better understand the relationship between obesity and outcomes of SARS-CoV-2 infection in patients with a left ventricular assist device (LVAD) or heart transplant. We performed a retrospective review of patients with a heart transplant or LVAD who presented to one of the participating 11 institutions between April 1 and November 30, 2020. Patients were grouped by body mass index (BMI) into obese (BMI ≥ 30 k/m2) and nonobese cohorts (BMI < 30 kg/m2). Multivariable logistic regression models were used to estimate effects of obesity on outcomes of interest. Across all centers, 162 heart transplant and 81 LVAD patients were identified; 54 (33%) and 38 (47%) were obese, respectively. Obese patients tended to have more symptoms at presentation. No differences in rates of hospitalization or ICU admission were noted. Obese patients with LVADs were more likely to require mechanical ventilation (39% vs. 8%, p < 0.05). No differences in renal failure or secondary infection were noted. Mortality was similar among heart transplant patients (11% [obese] vs. 16% [nonobese], p = 0.628) and LVAD patients (12% vs. 15%, p = 1.0). BMI was not associated with increased adjusted odds of mortality, ICU admission, or mechanical ventilation (all p > 0.10). In summary, acute presentations of SARS-CoV-2 among heart transplant and LVAD recipients carry a significantly higher mortality than the general population, although BMI does not appear to impact this. Further studies on the longer-term effects of COVID-19 on this population are warranted.